ATHE Alterity Therapeutics Limited: רווח למניה לשנה מתגלגלת

Alterity Therapeutics specializes in therapies for Parkinson's disease and multiple system atrophy, providing solutions to neurological centers. The business is based on creating molecules for brain metal regulation to prevent neuronal destruction. This daily price chart on GURU.Markets reflects an EPS TTM trend of 96.20. The Australian biotech firm is advancing R&D through clinical alliances with US clinics to validate the platform's efficacy.
פילוחי מדדים פיננסיים ומדדי שוק עבור Alterity Therapeutics Limited (ATHE)

Since the market capitalization of Alterity Therapeutics (ATHE) depends on the success of its Parkinson's disease therapy and future insurance reimbursements, the annual EPS TTM trend reflects the company's ability to generate earnings per share relative to the previous year. Growth in this indicator allows investors to identify hidden business deceleration or stagnation, which, in an environment of expensive credit, often leads to a downward asset revaluation.